Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.

Int J Environ Res Public Health

The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China.

Published: September 2015

AI Article Synopsis

  • HPV is the main cause of cervical cancer, and current vaccines primarily target HPV types 16 and 18, which may not be adequate for regions like China due to different HPV genotype distributions.
  • A study of 5,410 women with cervical cancer found that HPV-16 and -18 were responsible for significant percentages of various cancer types, but low-risk types included in the vaccine were less effective.
  • Adding HPV types 52 and 58 to the vaccine could enhance protection against cervical cancer and pre-cancerous conditions, suggesting a need for a more tailored vaccine for better efficacy in the Zhejiang Province.

Article Abstract

Human papillomavirus (HPV) are firmly established as the principal causative agent for cervical carcinoma. Current vaccines may provide some protection for women from cervical carcinoma linked to HPV genotype 16 and 18. This may be the best vaccine for Western women, but the geographical variation in HPV distributions may not make it the most appropriate vaccine for China or Asia. This study provided an observational, retrospective, hospital-based cross-sectional study on the distribution of HPV genotypes among 5410 women with invasive cervical cancer (ICC) or cervical intraepithelial neoplasia (CIN). Overall, the positive rates of the four HPV types included in current prophylactic vaccines were counted, the two high-risk types (HPV-16 and -18) covered by current vaccines represented 66.9% of women with squamous cancer, 55.0% with adenocarcinoma, 64.9% with adenosquamous carcinoma and 77.4% of other type ICC, as well as 59.5% of CIN III, 45.0% of CIN II and 38.1% of CIN I cases. As expected, two low-risk types (HPV-6 and -11) included in the quadrivalent vaccine did not show good coverage data. Particularly worth mentioning is the fact that the addition of HPV-52 and -58 to the vaccine cocktail would increase cancer protection in our population, potentially preventing up to beyond 16% of squamous/adenosquamous carcinoma and other type of cervical cancers, and 7.75% of adenocarcinomas. It might also potentially reduce the rate of CIN III by a further 28.6% and CIN II and I by a third. This study established the baseline for surveillance in Zhejiang Province, and provides data for further vaccine designs: a quadrivalent HPV vaccine covering HPV-16/-58/-18/-52, would be more welcome in our region in the forthcoming year compared to the currently available vaccine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586643PMC
http://dx.doi.org/10.3390/ijerph120910794DOI Listing

Publication Analysis

Top Keywords

cervical carcinoma
12
distribution hpv
8
hpv genotype
8
invasive cervical
8
cervical intraepithelial
8
intraepithelial neoplasia
8
zhejiang province
8
baseline surveillance
8
current vaccines
8
cin iii
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!